REG - IXICO plc - Grant of Share Options

IXICOAnnouncement

14/09/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220914:nRSN3417Za&default-theme=true

RNS Number : 3417Z  IXICO plc  14 September 2022

14 September 2022

 

IXICO plc

("IXICO" or the "Company")

 

Grant of Share Options

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering intelligent insights in neuroscience, today announces that it has
granted 600,000 options over the ordinary shares in the Company in accordance
with the rules of the Company's EMI Share Option Plan 2014 (the 'Plan').
These options have been awarded across twenty-four employees within the
Company and will be exercisable at a price of 29.3p (being at a 25% discount
to the closing middle market price per ordinary share on 13 September 2022).

 

The options are subject to performance conditions linked to revenues and
retention within the Company across three years.  No PDMR has received
options under this award.

 

The Company's Remuneration Committee has also reviewed the performance
conditions of the December 2019 and July 2020 LTIPs and, acting within the
share option scheme rules, amended the review of performance conditions to be
annually on the anniversary of each LTIP award. The vesting condition of 50%
of the respective award vesting on the third anniversary of the award, with
the remaining 50% of the respective award vesting on the fourth anniversary of
the award will remain.

 

For further information please contact:

 

 IXICO plc
 Giulio Cerroni, Chief Executive Officer           +44 (0)20 3763 7499

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                         +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUOSNRUNUKAAR